Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - VYNE Therapeutics Inc. | vyne-20201231xexx311.htm |
| 10-K - 10-K - VYNE Therapeutics Inc. | vyne-20201231.htm |
| EX-21.1 - EX-21.1 - VYNE Therapeutics Inc. | exhibit211listofsubsidiari.htm |
| EX-31.2 - EX-31.2 - VYNE Therapeutics Inc. | vyne-20201231xexx312.htm |
| EX-23.2 - EX-23.2 - VYNE Therapeutics Inc. | exhibit232consentisr.htm |
| EX-32.2 - EX-32.2 - VYNE Therapeutics Inc. | vyne-20201231xexx322.htm |
| EX-32.1 - EX-32.1 - VYNE Therapeutics Inc. | vyne-20201231xexx321.htm |
| EX-4.1 - EX-4.1 - VYNE Therapeutics Inc. | exhibit41.htm |
| EX-10.11C - EX-10.11C - VYNE Therapeutics Inc. | a1011c-formofrsuagreement2.htm |
| EX-3.1 - EX-3.1 - VYNE Therapeutics Inc. | exhibit31vynecertificateof.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-229482) and Form S-8 (Nos. 333-222758, 333-229975, and 333-237041) of VYNE Therapeutics Inc. of our report dated March 4, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, NJ
March 4, 2021